Literature DB >> 34525340

Resident memory CD8+ T cells in regional lymph nodes mediate immunity to metastatic melanoma.

Aleksey K Molodtsov1, Nikhil Khatwani1, Jennifer L Vella1, Kathryn A Lewis2, Yanding Zhao3, Jichang Han1, Delaney E Sullivan1, Tyler G Searles1, Nicholas K Preiss1, Tamer B Shabaneh1, Peisheng Zhang2, Aaron R Hawkes2, Brian T Malik1, Fred W Kolling2, Edward J Usherwood1, Sandra L Wong4, Joseph D Phillips4, Keisuke Shirai5, Christina V Angeles6, Shaofeng Yan7, Tyler J Curiel8, Yina H Huang9, Chao Cheng10, Mary Jo Turk11.   

Abstract

The nature of the anti-tumor immune response changes as primary tumors progress and metastasize. We investigated the role of resident memory (Trm) and circulating memory (Tcirm) cells in anti-tumor responses at metastatic locations using a mouse model of melanoma-associated vitiligo. We found that the transcriptional characteristics of tumor-specific CD8+ T cells were defined by the tissue of occupancy. Parabiosis revealed that tumor-specific Trm and Tcirm compartments persisted throughout visceral organs, but Trm cells dominated lymph nodes (LNs). Single-cell RNA-sequencing profiles of Trm cells in LN and skin were distinct, and T cell clonotypes that occupied both tissues were overwhelmingly maintained as Trm in LNs. Whereas Tcirm cells prevented melanoma growth in the lungs, Trm afforded long-lived protection against melanoma seeding in LNs. Expanded Trm populations were also present in melanoma-involved LNs from patients, and their transcriptional signature predicted better survival. Thus, tumor-specific Trm cells persist in LNs, restricting metastatic cancer.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CD69; CD8 T cells; CXCR6; Cancer; TCR; TRP-2; Trm; parabiosis; scRNA-seq; vitiligo

Mesh:

Year:  2021        PMID: 34525340      PMCID: PMC9015193          DOI: 10.1016/j.immuni.2021.08.019

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   43.474


  74 in total

Review 1.  The tumor-draining lymph node as an immune-privileged site.

Authors:  David H Munn; Andrew L Mellor
Journal:  Immunol Rev       Date:  2006-10       Impact factor: 12.988

2.  Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma.

Authors:  Mark B Faries; John F Thompson; Alistair J Cochran; Robert H Andtbacka; Nicola Mozzillo; Jonathan S Zager; Tiina Jahkola; Tawnya L Bowles; Alessandro Testori; Peter D Beitsch; Harald J Hoekstra; Marc Moncrieff; Christian Ingvar; Michel W J M Wouters; Michael S Sabel; Edward A Levine; Doreen Agnese; Michael Henderson; Reinhard Dummer; Carlo R Rossi; Rogerio I Neves; Steven D Trocha; Frances Wright; David R Byrd; Maurice Matter; Eddy Hsueh; Alastair MacKenzie-Ross; Douglas B Johnson; Patrick Terheyden; Adam C Berger; Tara L Huston; Jeffrey D Wayne; B Mark Smithers; Heather B Neuman; Schlomo Schneebaum; Jeffrey E Gershenwald; Charlotte E Ariyan; Darius C Desai; Lisa Jacobs; Kelly M McMasters; Anja Gesierich; Peter Hersey; Steven D Bines; John M Kane; Richard J Barth; Gregory McKinnon; Jeffrey M Farma; Erwin Schultz; Sergi Vidal-Sicart; Richard A Hoefer; James M Lewis; Randall Scheri; Mark C Kelley; Omgo E Nieweg; R Dirk Noyes; Dave S B Hoon; He-Jing Wang; David A Elashoff; Robert M Elashoff
Journal:  N Engl J Med       Date:  2017-06-08       Impact factor: 91.245

3.  Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.

Authors:  James Larkin; Vanna Chiarion-Sileni; Rene Gonzalez; Jean-Jacques Grob; Piotr Rutkowski; Christopher D Lao; C Lance Cowey; Dirk Schadendorf; John Wagstaff; Reinhard Dummer; Pier F Ferrucci; Michael Smylie; David Hogg; Andrew Hill; Ivan Márquez-Rodas; John Haanen; Massimo Guidoboni; Michele Maio; Patrick Schöffski; Matteo S Carlino; Céleste Lebbé; Grant McArthur; Paolo A Ascierto; Gregory A Daniels; Georgina V Long; Lars Bastholt; Jasmine I Rizzo; Agnes Balogh; Andriy Moshyk; F Stephen Hodi; Jedd D Wolchok
Journal:  N Engl J Med       Date:  2019-09-28       Impact factor: 91.245

4.  Survival of tissue-resident memory T cells requires exogenous lipid uptake and metabolism.

Authors:  Youdong Pan; Tian Tian; Chang Ook Park; Serena Y Lofftus; Shenglin Mei; Xing Liu; Chi Luo; John T O'Malley; Ahmed Gehad; Jessica E Teague; Sherrie J Divito; Robert Fuhlbrigge; Pere Puigserver; James G Krueger; Gökhan S Hotamisligil; Rachael A Clark; Thomas S Kupper
Journal:  Nature       Date:  2017-02-20       Impact factor: 49.962

5.  The proportion of circulating CD45RO+CD8+ memory T cells is correlated with clinical response in melanoma patients treated with ipilimumab.

Authors:  Julia K Tietze; Daniela Angelova; Markus V Heppt; Markus Reinholz; William J Murphy; Michael Spannagl; Thomas Ruzicka; Carola Berking
Journal:  Eur J Cancer       Date:  2017-02-27       Impact factor: 9.162

6.  The microanatomic location of metastatic melanoma in sentinel lymph nodes predicts nonsentinel lymph node involvement.

Authors:  D J Dewar; B Newell; M A Green; A P Topping; B W E M Powell; M G Cook
Journal:  J Clin Oncol       Date:  2004-08-15       Impact factor: 44.544

7.  CD69 acts downstream of interferon-alpha/beta to inhibit S1P1 and lymphocyte egress from lymphoid organs.

Authors:  Lawrence R Shiow; David B Rosen; Nadezda Brdicková; Ying Xu; Jinping An; Lewis L Lanier; Jason G Cyster; Mehrdad Matloubian
Journal:  Nature       Date:  2006-03-08       Impact factor: 49.962

8.  Association of Vitiligo With Tumor Response in Patients With Metastatic Melanoma Treated With Pembrolizumab.

Authors:  Camille Hua; Lise Boussemart; Christine Mateus; Emilie Routier; Céline Boutros; Hugo Cazenave; Roxane Viollet; Marina Thomas; Séverine Roy; Naima Benannoune; Gorana Tomasic; Jean-Charles Soria; Stéphane Champiat; Matthieu Texier; Emilie Lanoy; Caroline Robert
Journal:  JAMA Dermatol       Date:  2016-01       Impact factor: 10.282

9.  Human Tissue-Resident Memory T Cells Are Defined by Core Transcriptional and Functional Signatures in Lymphoid and Mucosal Sites.

Authors:  Brahma V Kumar; Wenji Ma; Michelle Miron; Tomer Granot; Rebecca S Guyer; Dustin J Carpenter; Takashi Senda; Xiaoyun Sun; Siu-Hong Ho; Harvey Lerner; Amy L Friedman; Yufeng Shen; Donna L Farber
Journal:  Cell Rep       Date:  2017-09-19       Impact factor: 9.995

10.  First-in-human phase 1 study of IT1208, a defucosylated humanized anti-CD4 depleting antibody, in patients with advanced solid tumors.

Authors:  Kohei Shitara; Satoshi Ueha; Shigeyuki Shichino; Hiroyasu Aoki; Haru Ogiwara; Tetsuya Nakatsura; Toshihiro Suzuki; Manami Shimomura; Toshiaki Yoshikawa; Kayoko Shoda; Shigehisa Kitano; Makiko Yamashita; Takayuki Nakayama; Akihiro Sato; Sakiko Kuroda; Masashi Wakabayashi; Shogo Nomura; Shoji Yokochi; Satoru Ito; Kouji Matsushima; Toshihiko Doi
Journal:  J Immunother Cancer       Date:  2019-07-24       Impact factor: 13.751

View more
  5 in total

1.  P2RX7 Enhances Tumor Control by CD8+ T Cells in Adoptive Cell Therapy.

Authors:  Kelsey M Wanhainen; Changwei Peng; Maggie H Zhou; Bruna de Gois Macedo; Stephen O'Flanagan; Tingyuan Yang; Ameeta Kelekar; Brandon J Burbach; Henrique Borges da Silva; Stephen C Jameson
Journal:  Cancer Immunol Res       Date:  2022-07-01       Impact factor: 12.020

2.  Standing Watch: Immune Activation and Failure in Melanoma Sentinel Lymph Nodes.

Authors:  Amanda W Lund
Journal:  Clin Cancer Res       Date:  2022-05-13       Impact factor: 13.801

Review 3.  Mechanisms and Clinical Significance of Tumor Lymphatic Invasion.

Authors:  Noriki Fujimoto; Lothar C Dieterich
Journal:  Cells       Date:  2021-09-29       Impact factor: 6.600

Review 4.  Functionalization of Nanomaterials for Skin Cancer Theranostics.

Authors:  Chao Zhang; Xinlin Zhu; Shuming Hou; Weihua Pan; Wanqing Liao
Journal:  Front Bioeng Biotechnol       Date:  2022-04-26

Review 5.  The evolving role of tissue-resident memory T cells in infections and cancer.

Authors:  Sasitorn Yenyuwadee; Jose Luis Sanchez-Trincado Lopez; Rushil Shah; Pamela C Rosato; Vassiliki A Boussiotis
Journal:  Sci Adv       Date:  2022-08-17       Impact factor: 14.957

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.